{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Out of the Blue: An AJRCCM Podcast","title":"Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-containing Regimens for Drug-sensitive TB: 12-Week Results","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/0b43af97\"></iframe>","width":"100%","height":180,"duration":899,"description":"Dr. John Fleetham chats with Dr. Kelly Dooley about her paper, \"Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-containing Regimens for Drug-sensitive TB: 12-Week Results.\"","thumbnail_url":"https://img.transistorcdn.com/XTsasvngOAZZAaByTQWhkMgOxWfLgyb6dj4pT1xppOQ/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS83MTVj/Y2I3OTljN2IzMDNk/MGM1ZmZiNDgyMWNi/Yjc5Ni5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}